Imatinib, a TKI capable of blocking PDGFR, although it has shown evident efficacy in various types of cancer, has not shown significant activity in high-grade gliomas, neither alone nor in association with hydroxyurea [86,87]. Here, PDGFRB is linked to central nervous system cancer.